Trial Profile
Cross-tumoral Phase 2 Clinical Trial Exploring Crizotinib (PF-02341066) in Patients With Advanced Tumors Induced by Causal Alterations of ALK and/or MET ("CREATE")
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Alveolar soft part sarcoma; Anaplastic large cell lymphoma; Clear cell sarcoma; Muscle tissue neoplasms; Renal cell carcinoma; Rhabdomyosarcoma
- Focus Therapeutic Use
- Acronyms CREATE
- 14 Feb 2023 Status changed from active, no longer recruiting to completed.
- 09 Feb 2023 This trial has been completed in Poland (Date of the global end of the trial: 30-Oct-2022), according to the European Clinical Trials Database record
- 31 Jan 2023 This trial has been completed in Netherlands, according to European Clinical Trials Database record.